{
  "ptid_time": "109_S_6364_2018-10-18",
  "img_path": "/data/qiuhui/data/adni/images/109_S_6364/2018-10-18/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 29,850 mm³, 60.3% above the reference mean. With a Z-score of 1.73 (95.8th percentile), this represents moderate enlargement; hippocampal volume measures 8,300 mm³, 6.3% above the reference mean. With a Z-score of 0.88 (81.0th percentile), this represents normal volume ; whole brain volume measures 1,168,140 mm³, 12.3% above the reference mean. With a Z-score of 1.47 (92.9th percentile), this represents mild enlargement; entorhinal cortex volume measures 2,677 mm³, 27.6% below the reference mean. With a Z-score of -2.16 (1.6th percentile), this represents significant atrophy; fusiform gyrus volume measures 20,002 mm³, 8.5% above the reference mean. With a Z-score of 0.77 (78.0th percentile), this represents normal volume ; middle temporal gyrus volume measures 23,624 mm³, 15.1% above the reference mean. With a Z-score of 1.24 (89.3th percentile), this represents mild enlargement. ",
  "text_data": "Age is 57.8 years. Gender is Female. Education: 18 years. MMSE: 28.0. MoCA: 27.0. Logical Memory: 10.0. APOEε4 alleles: 2.0. Biomarker levels: Flobetaben (FBB): 1.31 SUVR (profound elevated). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The entorhinal cortex shows significant atrophy (Z-score -2.16, 1.6th percentile), which is a strong biomarker for early Alzheimer's pathology. However, hippocampal volume is normal, and cognitive scores (MMSE 28, MoCA 27) are intact, suggesting no functional impairment. Ventricular enlargement may indicate some neurodegeneration but is not definitive alone.  \n\n**Diagnosis:** **Mild Cognitive Impairment (MCI)** (specifically, *prodromal Alzheimer's disease* given entorhinal atrophy and APOE4 homozygosity, but cognition is preserved).  \n\n**Confidence:** **Medium** (high confidence in biomarker evidence of neurodegeneration, but low confidence in MCI due to normal cognition; could also represent *preclinical AD*).  \n\n**Note:** APOE4 homozygosity (2 alleles) greatly increases AD risk, and entorhinal atrophy is an early sign. Follow-up with CSF biomarkers (Aβ42, p-tau) or amyloid PET would clarify. Current cognitive scores argue against dementia, but progression is likely.",
  "timestamp": "2025-07-26T11:36:28.189126"
}